Program 1: The expanding role of immunotherapy in HCC - Combining locoregional and systemic treatment in intermediate HCC addresses the following topics:
• The role of immunotherapy (IO) and IO combinations in the systemic treatment landscape for patients with unresectable HCC including the most recent trial data and guidelines
• The scientific rationale for and expanding role of IO for patients with intermediate unresectable HCC, including multimodal approaches
• The safety and efficacy of IO and IO-based treatments in combination with Locoregional therapy
• The importance of multidisciplinary care required for the optimal treatment of patients with intermediate HCC
https://cor2ed.com/hcc-connect/programmes/role-io-in-hcc/ Program 2: Advanced HCC - Treatment strategies for patients ineligible for immunotherapy or those with progression on immunotherapy addresses the following topics:
• 1st line treatment options for patients with HCC ineligible for IO
• Sequencing strategies, treatment options and available data after progression on IO
• When to switch after progression on 1st line IO
https://cor2ed.com/hcc-connect/programmes/navigating-advanced-hcc-treatment-strategies-beyond-immunotherapy-io/This activity is programmed by COR2ED and endorsed by AASLD. AASLD did not participate in the development of the programming.